Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease

Show other versions (1)

The overlapping clinical features of relapsing remitting multiple sclerosis (RRMS), aquaporin-4 (AQP4)-antibody (Ab) neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein (MOG)-Ab disease mean that detection of disease specific serum antibodies is the gold standard...

Full description

Bibliographic Details
Main Authors:	Jurynczyk, M, Probert, F, Yeo, T, Tackley, G, Claridge, T, Cavey, A, Woodhall, M, Arora, S, Winkler, T, Schiffer, E, Vincent, A, DeLuca, G, Sibson, N, Leite, M, Waters, P, Anthony, D, Palace, J
Format:	Journal article
Published:	BioMed Central 2017

Similar Items

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.
by: Jurynczyk, M, et al.
Published: (2017)

Distinguishing the brain MRI features of MS, AQP4-and MOG-antibody disease.
by: Jurynczyk, M, et al.
Published: (2016)

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
by: Juryńczyk, M, et al.
Published: (2016)

RELAPSING AQP4 ANTIBODY NEGATIVE NMO WITH MOG ANTIBODIES
by: Elsone, L, et al.
Published: (2014)

Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies
by: Yeo, T, et al.
Published: (2020)

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
by: Yeo, T, et al.
Published: (2019)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
by: Sato, D, et al.
Published: (2014)

Disease course and disability outcomes in MOG-antibody disease in the UK
by: Jurynczyk, M, et al.
Published: (2017)

International multicenter examination of MOG antibody assays
by: Reindl, M, et al.
Published: (2020)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
by: Kezuka, T, et al.
Published: (2014)

Clinical presentation and prognosis in MOG-antibody disease: a UK study
by: Jurynczyk, M, et al.
Published: (2017)

Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
by: Waters, P, et al.
Published: (2015)

Recurrent optic neuritis associated with MOG antibody seropositivity
by: Chang, T, et al.
Published: (2017)

No strong HLA association with MOG antibody disease in the UK population
by: Grant-Peters, M, et al.
Published: (2021)

An international multicentre validation experiment for MOG antibodies
by: Reindl, M, et al.
Published: (2018)

A 41-year-old woman with acute weakness and encephalopathy associated with MOG antibodies.
by: Morris, K, et al.
Published: (2015)

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
by: Waters, P, et al.
Published: (2015)

MOG-IgG1 antibodies in children
by: Waters, P, et al.
Published: (2018)

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
by: Jarius, S, et al.
Published: (2018)

Seronegative NMO: a sensitive AQP4 antibody test clarifies clinical features and next challenges.
by: Fujihara, K, et al.
Published: (2013)

Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.
by: Kaneko, K, et al.
Published: (2016)

Peripheral nervous system involvement in MOG antibody-associated demyelination
by: Ramanathan, S, et al.
Published: (2019)

THE ASSOCIATION OF TWO RARE NEUROLOGICAL DISEASES: A MULTICENTRE STUDY OF 16 PATIENTS WITH ACHR ANTIBODY MYASTHENIA GRAVIS AND AQP4 ANTIBODY NEUROMYELITIS OPTICA SPECTRUM DISORDER
by: Leite, M, et al.
Published: (2012)

AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD
by: Prain, K, et al.
Published: (2019)

Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
by: Piccolo, L, et al.
Published: (2016)

Glycine receptor antibodies: Clinical spectrum and pathogenic mechanisms of the antibodies
by: Carvajal, A, et al.
Published: (2012)

Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis
by: Tackley, G, et al.
Published: (2016)

Differential diagnosis and utility of AQP4-antibody assays in an insidious case of longitudinally extensive transverse myelitis
by: Rosellini, I, et al.
Published: (2009)

The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis
by: Messina, S, et al.
Published: (2021)

Anti-MOG Antibodies in Japanese Patients with Neuromyelitis Optica Spectrum Disorders
by: Sato, D, et al.
Published: (2014)

Assessment of aquaporin-4 (AQP4) antibody assays in European diagnostic centres
by: Waters, P, et al.
Published: (2014)

Serum antibodies in patients with epilepsy
by: Lang, B, et al.
Published: (2005)

Cell-based assay for anti-AQP4 antibody in Korean patients with neuromyelitis optica
by: Kim, B, et al.
Published: (2010)

Humoral signatures of MOG-antibody-associated disease track with age and disease activity
by: Spatola, Marianna, et al.
Published: (2023)

Anti-MOG Antibody Seropositive Patient Successfully Treated with Intermittent Rituximab Infusion
by: Kim, W, et al.
Published: (2014)

Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders
by: Rinaldi, S, et al.
Published: (2020)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
by: Waters, P, et al.
Published: (2016)

The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta.
by: Pachner, A, et al.
Published: (2003)

The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta.
by: Pachner, A, et al.
Published: (2003)

Strategies to Screen Anti-AQP4 Antibodies from Yeast Surface Display Libraries
by: Huang, Aric, et al.
Published: (2022)